Belite Bio Analysts See Potential For Stock Gains With Progress In Key Trials

After Belite Bio Inc (NASDAQ:BLTE) reported results, its stock has been under pressure.

The company reported its results amid an exciting earnings season. Here are some key analyst takeaways.

HC Wainwright On Belite Bio

Analyst Yi Chen maintained a Buy rating and price target of $100.

Belite Bio reported a net loss of $36.1 million, or $1.18 per share, "slightly higher than our estimated loss of $35.7M," Chen said in a note. Last month, the company announced positive results from "a pre-specified interim analysis of the pivotal Phase 3 DRAGON trial of ...